|Articles|January 19, 2017

WHO Warns of Potential Yellow Fever Outbreak in Brazil

Author(s)Carole Ellis

The World Health Organization issues a yellow fever outbreak warning in Brazil, a country that is already dealing with outbreaks of Zika virus, chikyngunya, and dengue.

The World Health Organization (WHO) has issued a yellow fever outbreak warning after receiving notification from the Brazil Ministry of Health (MoH) that the country suspects a total of 12 cases of yellow fever from six municipalities in a single state.

All 12 cases are males living in rural areas, and are between the ages of seven and 53 years. The first patient presented with symptoms on December 18, 2016, with the rest of the patients presenting with symptoms after that time. Health professionals have collected samples from all patients and sent them to the State Reference Laboratory for diagnosis of yellow fever, dengue, hantavirus, malaria, and additional diseases. On January 12, 2017, Brazil updated WHO on the potential outbreak event, revealing that a total of 110 suspected cases have been reported from 15 different communities in the same state. Furthermore, 30 deaths were reported, with 10 of those deaths confirmed to have been a direct result of yellow fever infection.

WHO noted in its risk assessment of the event, “Yellow fever outbreak has previously been detected in Minas Gerais. The most recent outbreak occurred a 2002-2003, when 63 confirmed cases, including 23 deaths, were detected.” Regarding this potential outbreak, the organization emphasized that the disease could spread rapidly due to relatively low vaccination coverage in the area. WHO also noted that transmission of the viral illness might extend into other states, such as Espírito Santo and southern Bahia, where extensive vaccination did not occur because the areas were previously considered to be at a low risk of transmission. “The introduction of the virus in these areas could potentially trigger large epidemics of yellow fever,” WHO warned. If infected humans travel from the local areas of infection to other areas with Aedes aegypti mosquito populations, the cycle of human-to-human transmission could spread via an infected mosquito population. In addition to this, Brazil is also dealing with outbreaks of Zika virus, chikyngunya, and dengue.

The Centers for Disease Control and Prevention recommended in their 2016 Yellow Book that individuals traveling from the United States to Minas Gerais and designated areas of Bahia get vaccinated for yellow fever before travel. A WHO spokespeople emphasized that vaccination is “highly recommended as a preventative measure” for both travelers and residents of any country where the disease is present. Since 2015, yellow fever vaccines have been limited and there ordering restrictions have been put into place in the United States. It takes 12 months to produce a new supply of yellow fever vaccines, and the vaccine stockpile has been replenished twice in 2016 alone.

At time of publication, WHO had not yet recommended restricted travel and trade to Brazil due to the yellow fever outbreak. Brazil’s MoH has sent teams to Minas Gerais to investigate the situation. While there, the teams will look into options for controlling disease vectors, such as mosquitoes, and conduct a house-to-house immunization campaign in areas where the population is already infected. Adjacent states to Minas Gerais are in the process of completing “preparedness activities for a potential introduction of yellow fever,” WHO reported.


Related to this article

Ebola Outbreak Tops 10,000 Cases as CDC Cites Spread to Kenya, Nigeria
The CDC reports the Bundibugyo virus outbreak in the Democratic Republic of the Congo (DRC) is now the second-largest Ebola outbreak on record. As of October 28, the agency counted 10,305 total confirmed cases and 4,996 total confirmed deaths. The overall risk to the American public and travelers remains low, and no cases tied to this outbreak have been confirmed in the US.
Measles Update: October 30, 2026
The latest CDC numbers show a 5.8% increase in measles cases from week-to-week, bringing the 2026 US total to more than double the amount seen in all of 2025 with 2 months left in the year.
Cefiderocol Continues to Show Activity Against Resistant Gram-Negative Infections
Shionogi data presented at IDWeek 2026 demonstrated a 76.7% clinical response with cefiderocol in carbapenem-resistant respiratory infections and high in vitro activity against resistant P aeruginosa VAP isolates. Christine Slover, PharmD, vice president, Infectious Diseases US Medical Affairs, Shionogi, offers insights on the data as well as clinical considerations for providers when weighing the antibiotic for patients.